esmo 2019: dr. mirza on important trials with parp inhibitors in ovarian cancer
Published 4 years ago • 626 plays • Length 8:29Download video MP4
Download video MP3
Similar videos
-
0:53
dr. mirza on the impact of parp inhibitors in ovarian cancer
-
1:35
dr. mirza on the phase iii nova trial in ovarian cancer
-
4:44
expert report on survival data from pivotal trials with parp inhibitors for brca-mut. ovarian cancer
-
2:58
standard of care updates in ovarian cancer: parp inhibitors
-
2:18
dr. mirza on efficacy of niraparib/bevacizumab combo in recurrent ovarian cancer
-
18:37
ongoing clinical trials with parp inhibitors in ovarian cancer
-
2:18
dr. mirza on final data of the nsgo-avanova2/engot-ov24 trial in ovarian cancer
-
3:45
parp inhibitors for ovarian cancer
-
0:52
dr. mirza on safety profile of niraparib/bevacizumab in recurrent ovarian cancer
-
1:15:03
onclive news network on location: esmo 2019 day 3
-
6:20
parp inhibitors in recurrent ovarian cancer
-
3:58
the potential of parp inhibitors in ovarian cancer: paola-1, prima & velia
-
2:11
dr. mirza on the rationale for the avanova trial in recurrent ovarian cancer
-
10:36
parp inhibitor trial updates
-
1:30
dr. mirza on the evolving treatment landscape in recurrent ovarian cancer
-
1:41
parp inhibitors at the crossroads in ovarian cancer: 2022 esmo florida
-
2:03
dr. moore on treatment for patients with ovarian cancer who develop resistance to parp inhibitors
-
2:18
#esmo21 highlights on maintenance olaparib in ovarian cancer previously treated with parpi
-
2:26
dr. mirza discusses niraparib dose modifications for ovarian cancer patients with low body weight